Johnson & Johnson announces completion of Cordis divestiture to Cardinal Health
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) has announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments. The Cordis business is a global leader in the development and manufacture of interventional vascular technology and generated net revenues of approximately $780 million in 2014.
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
- Details
- Category: Novartis
Novartis announced today a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya® (fingolimod). The analysis evaluated the proportion of Gilenya patients with relapsing multiple sclerosis (RMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years[1].
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax. "The addition of Nimenrix and Mencevax helps us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide," said Susan Silbermann, president and general manager, Pfizer Vaccines.
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care
- Details
- Category: Genzyme
Genzyme, a Sanofi company, today announced a new global initiative, vs.MS, that is designed to raise awareness of the often unspoken emotional and physical burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. To better understand the full burden associated with RMS, Genzyme fielded a global survey among more than 1,500 people living with RMS and their care partners across seven countries.
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
- Details
- Category: AstraZeneca
The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies - AMAGINE-2 and AMAGINE-3 - demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.
New Roche Esbriet data show clinical benefits of continued and long-term treatment in patients with idiopathic pulmonary fibrosis (IPF)
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that new clinical data and abstracts on Esbriet® (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS) congress in Amsterdam. A pooled analysis from the ASCEND and CAPACITY phase III studies showed a 38% reduction in risk of death (p=0.0515) in IPF patients who stayed on Esbriet treatment up to two years (120 weeks) compared with placebo.(1)
Merck's Consumer Health business counts on Latin America for growth
- Details
- Category: Merck Group
Merck, a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials, expects the Latin America region to keep driving growth at its Consumer Health business, as demand for consumer goods in the region is constantly rising.
More Pharma News ...
- Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
- Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
- Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement
- Lilly Diabetes launches new Disney book for families affected by type 1 diabetes
- New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin
- Daiichi Sankyo signs agreement with Translational Sciences, Inc. to develop and commercialize the first-in-class thrombus dissolving agent, TS23
- Abbott is asking one million people worldwide. Here's why and how.